Cullinan Associates Inc. Sells 600 Shares of Danaher Co. (NYSE:DHR)

Cullinan Associates Inc. reduced its position in shares of Danaher Co. (NYSE:DHR) by 25.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,800 shares of the conglomerate’s stock after selling 600 shares during the period. Cullinan Associates Inc.’s holdings in Danaher were worth $449,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in DHR. Cape Investment Advisory Inc. acquired a new position in Danaher in the 4th quarter valued at $25,000. Tsfg LLC increased its stake in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the last quarter. BKM Wealth Management LLC bought a new stake in Danaher during the 4th quarter worth $27,000. Wetzel Investment Advisors Inc. bought a new stake in Danaher during the 4th quarter worth $29,000. Finally, Rakuten Securities Inc. bought a new stake in Danaher during the 4th quarter worth $36,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares in the company, valued at approximately $28,304,483.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares in the company, valued at approximately $28,304,483.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 4,000 shares of the firm’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the transaction, the senior vice president now owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 148,783 shares of company stock worth $37,536,717. Insiders own 10.90% of the company’s stock.

Danaher Trading Down 1.7 %

Shares of NYSE DHR opened at $240.41 on Wednesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The business’s 50 day moving average price is $256.13 and its 200-day moving average price is $246.86. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $269.11. The company has a market cap of $178.07 billion, a price-to-earnings ratio of 40.75, a PEG ratio of 3.82 and a beta of 0.84.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. Danaher’s revenue was down 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.36 earnings per share. On average, sell-side analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, June 28th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s dividend payout ratio is presently 18.31%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on DHR shares. Barclays upped their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 24th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Robert W. Baird upped their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Jefferies Financial Group initiated coverage on Danaher in a report on Monday, June 3rd. They set a “buy” rating and a $295.00 price target for the company. Finally, Bank of America upped their price objective on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $268.67.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.